Navigation Links
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
Date:7/8/2008

20 mg/day and 30 mg/day), Concerta (36 mg/day and 54 mg/day) and placebo.

Primary efficacy was measured by the change from pre-dose in the Swanson, Kotkin, Agler, Mylnn, and Pelham (SKAMP) Rating Scale-Combined scores at two hours post-dose with Focalin XR 20 mg compared with Concerta 36 mg. The SKAMP rating scale is a standard assessment tool used in laboratory classroom clinical trials to evaluate attention and behavior.

Both doses of Focalin XR showed significantly greater improvement in SKAMP-Attention and -Deportment scores when compared with placebo at all measured time-points (30 minutes to 12 hours post-dose), except for 10-12 hours post-dose with 20 mg. Concerta 36 mg and 54 mg demonstrated efficacy at measured time-points 1-12 hours post-dose, but were no different to placebo at 30 minutes.

Because of the differences in release profiles, the investigators also studied overall efficacy during the 12 hour study period using an area under the curve analysis (AUC0-12) of the SKAMP combined scores. All doses of the active medication were significantly better than placebo. There was no difference between Focalin XR 20 mg and 30 mg when compared to both Concerta 36 mg and 54 mg, respectively, observed overall across the 12-hour day.

In general, both treatments were well tolerated and no patients discontinued or had a reduction in study drug dose due to an adverse event. A total of 81 children completed the study (three withdrew consent for reasons not related to study medications).

A previous head-to-head study comparing Focalin XR and Concerta published in the April 2008 Psychopharmacology Bulletin found similar efficacy and safety results to the present study.

About Focalin XR

Focalin XR (dexmethylphenidate HCl) extended-release capsules are indicated for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in adults, adolescents and children six years and older. Focalin XR is indicated as an integral
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
2. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
3. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  According to their CEO, Rob Bohacs ... is going through a complete transformation with highly ... the current clinical trial management process isn,t configured ... trials, which will ultimately drive the prescription cancer ... has been recognized by the National Cancer Institute as ...
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... -- A study using a relatively new imaging tool, ... the composition of carotid artery disease and has the ... disease, a leading cause of stroke. ... 2010 and May 2012, was featured in the June ... College of Cardiology (JACC) Cardiovascular Interventions. Interventional cardiologist ...
Breaking Medicine Technology:Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
...  Qforma, the leading provider of healthcare analytics and predictive ... appointment of Ian McGuinness to the position of Vice ... to welcome Ian to our team as we continue ... the pharmaceutical business," said Al Reicheg, Chief Commercial Officer ...
... PRUSSIA, Pa., Dec. 19, 2011  Medical Alarm Concepts ... first fully-monitored medical alarm system that allows you ... today announced its plans to promote the MediPendant™ ... for Costco and its members. ...
Cached Medicine Technology:Qforma Appoints Ian McGuinness as Vice President, Business Development 2Medical Alarm Concepts™ Chosen as a Strategic Alliance Partner with Costco Warehouse Clubs 2
(Date:10/1/2014)... co-funded by the Engineering and Physical Sciences Research ... the UK,s vital industrial control systems which run, ... grid, and the rail network. , The ... hackers or malware infiltrating the systems behind our ... in Trustworthy Industrial Control Systems (RITICS), based at ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new ... retired couples. , Senior citizens can purchase a ... their loved ones. A joint policy is cheaper, but ... away. , Life insurance can be used to ... even be purchased online, as the application process is ...
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 Beverly ... Dr. Kathleen Mojas is celebrating 20 years of private ... assisted hundreds of people to achieve greater joy and ... important list of warning signs and suggestions for anyone ... Dr. Mojas explains: “Believe it or not, it’s ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... Calif., Jan. 15 Abaxis, Inc.,(Nasdaq: ABAX ... systems, announced today that Clint Severson, CEO and,President, ... Company Emerging,Growth Conference on Wednesday, January 23, 2008 ... at The Ritz-Carlton, Palm Beach Florida., About ...
... incidence of liver cancer continues to grow-- fueled in large ... too does the need for tests to help diagnose the ... in the January 15 issue of Clinical Cancer Research demonstrates ... more accurate than traditional biomarkers in distinguishing liver cancer patients ...
... 14 Access,Pharmaceuticals, Inc. (OTC Bulletin Board: ... pharmaceutical company focused on bringing,proprietary medicines to ... of a,definitive licensing agreement under which RHEI, ... penetrating large volume hospitals, will,market Access,s proprietary ...
... MINRAD,International, Inc. (Amex: BUF ) today announced the ... Jr. as the new Chief,Financial Officer and Executive Vice ... from Hardinge, Inc., where he has been the,Chief Financial ... he served as the Chief Financial Officer and Treasurer ...
... American Physical Therapy Association Sponsors National Toll-Free,Hotline Addressing Ways ... ALEXANDRIA, Va., Jan. 14 Falls are,prevalent, dangerous, and ... nearly one in two seniors over age 80, will ... consequences.* As our nation,s population,ages, the rate of falls ...
... 14 The Lake Forest Hospital,Foundation board of directors ... create a new health care system for northeastern Illinois,and ... by a,combination of both hospital boards and would bring ... consumer ranked hospitals in,Lake County.*, As part of ...
Cached Medicine News:Health News:Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer 2Health News:Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer 3Health News:Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries 2Health News:Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries 3Health News:MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP 2Health News:MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP 3Health News:Physical Therapist Intervention for Balance Impairments May Help Reduce Risk of Falling 2Health News:Physical Therapist Intervention for Balance Impairments May Help Reduce Risk of Falling 3Health News:Physical Therapist Intervention for Balance Impairments May Help Reduce Risk of Falling 4Health News:Lake Forest Hospital Proposes a New Health Care System in Lake County 2
... The Vasotrax is an ... pressure and heart rate non-invasively, ... fact, significantly more accurate than ... On a full battery charge, ...
... are heterodimeric proteins that suppress the secretion ... pituitary. Inhibin consists of two distinct chains, ... Inhibin A consists of the alpha-subunit and ... and betaB-subunit. Only the dimeric forms of ...
... (IGF-II) is a 7.5 kDa peptide which is ... to have mitogenic and metabolic actions involved in ... by binding to target cell receptors. IGF-II binds ... receptor, a monomeric protein which also serves as ...
... Pregnancy-associated plasma protein A (PAPP-A) is ... is produced in high concentrations by ... into the maternal circulation in increasing ... PAPP-A is not specific to pregnancy ...
Medicine Products: